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Letters
INCREASING BURDEN OF ANTIMICROBIAL 
RESISTANCE IN PSEUDOMONAS 
AERUGINOSA FROM ADULT PATIENTS WITH 
CYSTIC FIBROSIS (CF) IN NORTHERN IRELAND: 
THEN AND NOW
Editor,
Cystic fibrosis (CF) is characterised by defective mucociliary 
clearance and chronic airway infection.1  The most commonly 
isolated pathogen from CF airways is a Gram-negative 
bacterium, Pseudomonas aeruginosa (PA).2  Chronic 
PA infection is associated with significant morbidity and 
mortality in CF patients3 and necessitates multiple antibiotic 
courses.2 Antimicrobial resistance (AMR) in PA may be 
driven by the exposure of bacterium to antibiotic, either in the 
acute setting or during anti-pseudomonal chronic suppressive 
therapy.  We examined AMR from PA isolates from a single 
adult CF centre, by comparing antibiotic susceptibility from 
contemporary isolates with a collection from 13 years ago.
Two collections of PA isolates were examined, each consisting 
of 100 non-duplicated organisms, which had isolated from 
the sputum of adult CF patients attending the Northern 
Ireland Adult Cystic Fibrosis Centre, Belfast City Hospital. 
Collection A was isolated during the period 1996-2001 
and Collection B (2015-2016).  Microbiological isolation 
of PA was performed from freshly expectorated sputum, 
by employment of selective culture for 24-48h, followed 
by biochemical confirmation with API20NE identication 
strips (Biomerieux Ltd, UK). Antibiotic susceptibility was 
performed on each isolate by standard disk diffusion assay and 
resulting zone sizes were interpreted against published CLSI 
criteria.  Eight antibiotics from three classes of antibiotics 
were examined, including beta-lactams, fluoroquinolone and 
polymyxin, as detailed in Figure 1.  Antibiotic susceptibility 
was quantified by employment of a novel marker, Relative 
Resistance Index [RRI], as recently described.4  Briefly, 
qualitative “sensitive”, “moderately resistant” and “resistant” 
data were converted into a quantitative RRI value, through 
employment of an algorithm.4 An unpaired two-tailed t-test 
was used for comparison of trends between these two periods 
and a probability (p) value of less than 5% (p<0.5) was 
considered statistically significant.  There were no differences 
in the microbiological isolation methodology nor with the 
antibiotic susceptibility methodology between these two 
collection periods.
A comparison of RRI scores between the two collection periods 
is shown (Figure 1).  RRI and AMR increased significantly 
for ciprofloxacin (p<0.0001)***, aminoglycosides (both 
amikacin and tobramycin, p<0.0001)*** and meropenem 
(p<0.0001)*** for PA isolates from 1996-2001 to 2015-
2016. There was reduction in AMR during this period with 
piperacillin/tazobactam and ceftazidime.
Overall, this study showed markedly greater resistance in the 
2015-2016 PA cohort. Increase in AMR may reflect chronic 
exposure of PA to several classes of antibiotics used in the 
management of CF airways infection. Until now, it has been 
relatively difficult to perform comparative studies on AMR 
in CF, due to the reliance on generating largely qualitative 
data (S, I &R) from disk diffusion assay.  However, RRI 
may help tracking changes in resistance patterns either at a 
population level or at an individual patient level, either with 
a single antibiotic agent, several agents within a single class 
or collectively between antibiotic classes.
This approach may be useful in helping to track emergence 
in AMR epidemiologically, those agents which display 
the greatest shift in AMR, as well as helping to guide 
antimicrobial stewardship practices and policies in CF.  
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Figure 1 Change in mean Relative Resistance Index [RRI] over a 13 year period with respect to Pseudomonas aeruginosa
isolates (n=200) from the sputum of adult CF patients
Antibiotic Piperacillin/
Tazobactam
Ceftazidime Meropenem Aztreonam Tobramycin Amikacin Ciprofloxacin Colistin
RRI 1996-2001 1.65 1.68 1.36 1.70 1.14 1.26 1.37 1.02
RRI 2015-2016 1.38 1.62 1.77 1.73 1.84 2.30 1.96 1.11
p value 0.02* 0.6 <0.0001*** 0.8 <0.0001*** <0.0001*** <0.0001*** 0.056
Fig 1. Change in mean Relative Resistance Index [RRI] over a 
13 year period with respect to Pseudomonas aeruginosa isolates 
(n=200) from the sputum of adult CF patients
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